{"entity":{"id":"nct06091254","kind":"trial","name":"A Trial to Learn if Odronextamab is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Different Types of Chemotherapy ","aka":["OLYMPIA-1"],"tldr":"A phase 3 trial of Odronextamab, Rituximab, Cyclophosphamide in follicular lymphoma, run by Regeneron Pharmaceuticals, now recruiting.","summary":"A Trial to Learn if Odronextamab is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Different Types of Chemotherapy for Adult Participants With Previously Untreated Follicular Lymphoma is a phase 3 interventional study registered as NCT06091254 by Regeneron Pharmaceuticals, with 822 participants planned, started 2023-12-12 and due to reach its primary completion in 2028-02-07. Interventions recorded: Odronextamab, Rituximab, Cyclophosphamide, Doxorubicin, Vincristine. Conditions listed: Follicular Lymphoma (FL). No results are recorded here; the registry entry is the source.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT06091254","url":"https://clinicaltrials.gov/study/NCT06091254"}],"tags":["ctgov-ingest"],"related":[],"cancers":["follicular-lymphoma"],"sections":[],"technologies":["monoclonal-antibody","t-cell-engager"],"targets":[],"drugs":["odronextamab","rituximab","cyclophosphamide","doxorubicin","vincristine","prednisone"],"companies":["regeneron"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT06091254","phase":"3","setting":"A Phase 3, Open-label, Randomized Study to Compare the Efficacy and Safety of Odronextamab (REGN1979), an Anti-CD20 X Anti-CD3 Bispecific Antibody Versus Investigator's Choice in Previously Untreated Participants With Follicular Lymphoma (OLYMPIA-1)","sponsor":"Regeneron Pharmaceuticals","participation":[{"nct":"NCT06091254","source":"https://clinicaltrials.gov/study/NCT06091254","fetchedAt":"2026-10-07T16:54:11.803Z","studySha256":"912a6f83d5dfbb08ab52ed77bef6cb2d15544c4dc4796ae8e77b1c920137ba66","overallStatus":"RECRUITING","lastUpdatePosted":"2026-10-06","leadSponsor":"Regeneron Pharmaceuticals","collaboratorCount":0,"minimumAge":"18 Years","sex":"ALL","healthyVolunteers":false,"hasEligibility":true,"enrolment":822,"enrolmentType":"ESTIMATED","siteCount":190,"recruitingSiteCount":145,"countries":["Australia","Austria","Belgium","Brazil","Canada","Chile","Czechia","France","Germany","Israel","Italy","Poland","South Korea","Spain","Switzerland","Taiwan","Turkey (Türkiye)","United Kingdom","United States"]}],"started":"2023-12-12","startedType":"actual","enrolled":822,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct06091254/","neighbours":{"cancer":[{"id":"follicular-lymphoma","kind":"cancer","name":"Follicular lymphoma","route":"/cancers/follicular-lymphoma/"}],"technology":[{"id":"monoclonal-antibody","kind":"technology","name":"Monoclonal antibodies","route":"/technologies/monoclonal-antibody/"},{"id":"t-cell-engager","kind":"technology","name":"T-cell engagers (bispecific)","route":"/technologies/t-cell-engager/"}],"drug":[{"id":"cyclophosphamide","kind":"drug","name":"Cyclophosphamide","route":"/drugs/cyclophosphamide/"},{"id":"doxorubicin","kind":"drug","name":"Doxorubicin","route":"/drugs/doxorubicin/"},{"id":"odronextamab","kind":"drug","name":"Odronextamab","route":"/drugs/odronextamab/"},{"id":"prednisone","kind":"drug","name":"Prednisone","route":"/drugs/prednisone/"},{"id":"rituximab","kind":"drug","name":"Rituximab","route":"/drugs/rituximab/"},{"id":"vincristine","kind":"drug","name":"Vincristine","route":"/drugs/vincristine/"}],"company":[{"id":"regeneron","kind":"company","name":"Regeneron","route":"/companies/regeneron/"}]}}